Back to search

Switzerland· 67359001

Piqray 150 mg, Filmtabletten

A alpelisib product containing alpelisibum, registered in Switzerland by Novartis Pharma Schweiz AG and dispensed under Swissmedic category A, on the national reimbursement list. The same ATC class is registered in 12 of our 19 countries.

Reimbursed in Switzerland (BAG SL)Cat A (Swissmedic)ATC L01EM03

Checked against Swissmedic (Switzerland) on

Informational only — not a medical device.

SOURCE REGISTER · CHSwissmedic (Switzerland)normalisedPiqray 150 mg, FilmtablettenATCL01EM03REGISTER NO.67359001PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Alpelisib is registered in 12 of 19 countries.

Countries holding a registration under ATC L01EM03 (alpelisib), each read from that country’s own register.

  • This record: Switzerland, from Swissmedic (Switzerland)
  • 8 of them publish a price we can compare per daily dose

Alpelisib · ATC L01EM03

12 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of alpelisib costs, country by country.

Normalised to the WHO defined daily dose (0.3 g), so markets compare like for like.

  • Switzerland: $136.30 per daily dose (median across products in the class)
  • Public list prices, converted to USD at the rate date shown

Alpelisib · price per daily dose (0.3 g)

USD · FX 28 Sept 2026

  • CH Switzerland$136.30
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

Swissmedic (Switzerland)
Active substance
alpelisibum
Manufacturer
Novartis Pharma Schweiz AG
Country
Switzerland (CH)
ATC code
L01EM03
ATC class
Alpelisib
Defined daily dose
0.3 g, O
Swissmedic category
A
Reimbursed
Yes
Source register
Swissmedic (Switzerland)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • gtin
    7680673590010
    Blist 28 Stk
    CHF 1582.55

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

347 interactions on record for alpelisib.

Graded by severity as the source publishes them — 14 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Alpelisib · interactions on record

347 records

  • 14 severe
  • 329 moderate
  • 4 minor

Most severe, free to view

  • EdoxabanB01AF03severe
  • RifampicinJ04AB02severe
  • RifabutinJ04AB04severe
  • RifapentineJ04AB05severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Alpelisib in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All alpelisib products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Piqray, Vijoice
  • Liechtenstein · Piqray, Vijoice
  • Norway · Piqray, Vijoice

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/1252ca48-716b-4dda-96e4-8d8c232c8385
GET /v1/drugs/1252ca48-716b-4dda-96e4-8d8c232c8385?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "unit": null,
  "strength": "alpelisibum 150 mg",
  "valid_from": "2024-03-01",
  "limitations": "[{\"description\":\"Zur Behandlung ausschliesslich in Kombination mit Fulvestrant von postmenopausalen Frauen mit Hormon-Rezeptor (HR)-positivem, humanen epidermalen Wachstumsfaktor-Rezeptor-2 (HER2)-negativem lokal fortgeschrittenem oder metastasiertem Brustkrebs mit einer PIK3CA-Mutation nach Fortschreiten der Erkrankung, wenn die Patienten zuvor eine endokrine Therapie einschliesslich eines Aromatase Inhibitors erhalten haben:<br>\\n‒ als Erstlinientherapie im fortgeschrittenen Stadium nach Progression während neoadjuvanter oder adjuvanter endokriner Therapie oder nach Rezidiv innerhalb von 12 Monaten nach Abschluss der adjuvanten endokrinen Therapie.<br>\\n‒ als Zweitlinientherapie nach Versagen der endokrinen Erstlinientherapie im fortgeschrittenen Stadium.<br>\\nKein Einsatz bei viszeraler Krise.<br>\\nKeine vorangehende Chemotherapie (ausser neoadjuvant/adjuvante Chemotherapie).<br>\\nKeine vorangehende Therapie mit einem der folgenden Arzneimittel: Fulvestrant, PI3K-Inhibitor, mTOR-Inhibitor oder AKT-Inhibitor.<br>\\nDie Patienten dürfen maximal bis zur Progression der Erkrankung behandelt werden.<br>\\nDie Zulassungsinhaberin erstattet dem Krankenversicherer, bei dem die versicherte Person zum Zeitpunkt des Bezugs versichert war, auf dessen erste Aufforderung hin auf jede bezogene Packung Piqray einen festgelegten Betrag des Fabrikabgabepreises zurück. Sie gibt dem Krankenversicherer die Höhe der Rückvergütung je Packungsgrösse und Dosisstärke bekannt. Die Mehrwertsteuer kann nicht zusätzlich zu diesen Rückvergütungsbeträgen zurückgefordert werden. Die Aufforderung zur Rückvergütung soll ab dem Zeitpunkt der Verabreichung erfolgen.<br>\\n<br>\",\"costApproval\":null,\"indication\":\"21067.01\",\"isNew\":false,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2024-03-01\",\"validTo\":\"2027-02-28\"}]",
  "galenic_form": "Filmtabl 150 mg",
  "therapeutic_area": null,
  "sl_inclusion_date": "2021-03-01",
  "self_retention_pct": 10
}

See everything about alpelisib.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.